Table 2. Genotype and allele frequencies.

APOE2 homozygotes
Genotype/allele frequencya	Type III HLP, N (%)	NORMO, N (%)	NDCP, N (%)	HTG, N (%)
APOC3 3238 G>C
GG	78 (69.6)	44 (86.3)*	123 (83.9)**	71 (61.7)
GC	33 (29.5)	7 (13.7)	23 (15.4)	38 (33.0)
CC	1 (0.9)	0 (0.0)	1 (0.7)	6 (5.2)
1	189 (84.4)	95 (93.1)*	273 (92.6)*	180 (78.3)
2	35 (15.6)	7 (6.9)	25 (7.4)	50 (21.7)
95 % CI	1.11–1.20	1.02–1.12	1.05–1.12	1.16–1.27
APOA5 −1131 T>C
TT	75 (70.8)	45 (88.2)*	127 (88.2)**	67 (58.3)*
TC	30 (28.3)	6 (11.8)	16 (11.1)	42 (36.5)
CC	1 (0.9)	0 (0.0)	1 (0.7)	6 (5.2)
1	180 (84.9)	96 (94.1)*	270 (93.7)**	176 (76.5)*
2	32 (15.1)	6 (5.9)	18 (6.3)	54 (23.5)
95 % CI	1.10–1.20	1.01–1.10	1.03–1.09	1.18–1.29
APOA5 c.56 G>C
GG	84 (79.2)	46 (90.2)	114 (85.1)	85 (67.5)
GC	19 (17.9)	5 (9.8)	20 (14.9)	35 (27.8)
CC	3 (2.8)	0 (0.0)	0 (0.0)	6 (4.8)
1	187 (88.2)	97 (95.1)	248 (92.5)	205 (81.3)
2	25 (11.8)	5 (4.9)	20 (7.5)	47 (18.7)
95 % CI	1.01–1.16	1.01–1.10	1.04–1.1	1.14–1.24
LPL c.27 G>A
GG	100 (88.5)	51 (98.1)*	144 (94.7)*	103 (90.4)
GA	12 (10.6)	1 (1.9)	8 (5.3)	11 (9.6)
AA	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)
1	212 (93.8)	103 (99.0)*	296 (97.4)*	217 (95.2)
2	14 (6.2)	1 (1.0)	8 (2.6)	11 (4.8)
95 % CI	1.03–1.09	0.99–1.03	1.01–1.04	1.02–1.08

95% CI: 95% confidence interval; type III HLP: type III hyperlipidemic patients; normo: normolipidemic E2/2 subjects; NDCP: normal Dutch control panel; HTG: hypertriglyceridemic patients.

^a1 represents common allele frequency; 2 represents rare allele frequency.

^*Significant difference genotype/allele frequency (P<0.05) with type III HLP.

^**Significant difference genotype/allele frequency (P<0.01) with type III HLP.

Differences between genotype or allele frequencies are based on linear-by-linear association.